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ABSTRACT
Objectives: The Medical Outcomes Study Short Form
36-Item Health Survey (SF-36) is the most widely used
generic instrument to estimate quality of life of patients on
renal replacement therapy. Purpose of this study was to sum-
marize and compare the published literature on quality of life
of hemodialysis (HD), peritoneal dialysis (PD), and renal
transplant (RTx) patients.
Methods: We used random-effects regression analyses to
compare the SF-36 scores across treatment groups and
adjusted this comparison for age and prevalence of diabetes
using random-effects meta-regression analyses.
Results: We found 52 articles that met the inclusion criteria,
reporting quality of life of 36,582 patients. The unadjusted
scores of all SF-36 health dimensions were not signiﬁcantly
different between HD and PD patients, but the scores of RTx
patients were higher than those of dialysis patients, except for
the dimensions Mental Health and Bodily Pain. Point differ-
ences between dialysis and RTx patients varied from 2 to 32.
With adjustment for age and diabetes, the differences became
smaller (point difference 2–22). The signiﬁcance of the dif-
ferences of both dialysis groups compared with RTx recipi-
ents disappeared for the dimensions Vitality and Social
Functioning. The signiﬁcance of the differences between HD
and RTx patients disappeared on the dimensions Physical
Functioning, Role Physical, and Bodily Pain.
Conclusion: We conclude that dialysis patients have a lower
quality of life than RTx patients, but this difference can
partly be explained by differences in age and prevalence of
diabetes.
Keywords: hemodialysis, meta-analysis, peritoneal dialysis,
quality of life, renal transplantation.
Introduction
Because survival among patients with end-stage renal
disease (ESRD) is improving, health-related quality
of life is becoming more important as an outcome
measure in the evaluation of the various renal replace-
ment therapies (RRTs) and other therapeutic interven-
tions for these patients. Moreover, it has been argued
that quality of life of patients on RRT can predict their
future morbidity and mortality [1–4]. In general, mea-
surement of health-related quality of life is becoming
more important; not only as an outcome measure in
chronic disease but also as an adjustment factor in
economic evaluations.
Reﬂecting the increasing interest, the body of
literature on quality of life among patients on RRT has
expanded rapidly in recent years. Of the RRTs, renal
transplantation (RTx) is generally accepted as the
preferred treatment for ESRD. As early as the 1980s,
Evans et al. reported that quality of life is higher
among RTx recipients compared with dialysis patients
[5]. Other authors, however, reported that this might
be explained by pre-existing differences between
patients selected for the different forms of RRT [6],
including differences in age, sex, ethnicity, primary
renal disease, and comorbidity. This study however,
included only a small number of PD and RTx patients.
Studies on the difference in health-related quality of
life of hemodialysis (HD) compared with that of peri-
toneal dialysis (PD) patients remain controversial.
Some studies show a higher quality of life for PD
patients as compared with hospital HD patients [5,7],
whereas others found similar physical quality of life
for PD and HD patients, but higher mental quality of
life for PD patients [8]. Thus, considerable uncertainty
remains as to the differences in quality of life of HD
and PD patients and as to the differences in quality of
life of dialysis patients and RTx patients when adjusted
for covariates.
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When confronted with such a large body of litera-
ture with disparate results it can be helpful to perform
a systematic review and meta-analysis, adjusting for
covariates where possible. Previously, Cameron and
colleagues performed a meta-analysis of the literature
on quality of life associated with RRTs. Nevertheless,
this study reviewed the literature on emotional distress
and/or psychological well-being measures and did not
include measures of health-related quality of life [6].
The Medical Outcomes Study Short Form 36-Item
Health Survey (SF-36) is the most widely used generic
quality-of-life assessment instrument to estimate
quality of life of patients with ESRD [9]. It has shown
to be valid [10], sensitive to treatment changes [11],
and to be accepted by ESRD patients [12].
The purpose of our study was therefore to summa-
rize the published literature on the SF-36 as a measure
of health-related quality of life of patients receivingHD,
PD, andRTx. Furthermore, our aimwas to compare the
SF-36 scores across treatment groups adjusted for age
and prevalence of diabetes as comorbidity.
Methods
Study Retrieval
An English literature search was performed using
MEDLINE (United States National Library of Medi-
cine, Bethesda, MD, USA) and PsycINFO (Web SPIRS,
Silver Platter, New York, NY, USA). All articles from
peer-reviewed journals, published before June 2005
were considered for inclusion. Additional studies were
identiﬁed through the bibliographies of the articles.
Studies were included if they met the following criteria:
1) they reported all SF-36 dimension scores; 2) they
included at least one of the forms of RRT speciﬁed as
HD, PD or RTx; 3) data were collected prospectively;
and 4) the sample size was at least 10 patients per
treatment group. Articles were excluded if the data
were provided by proxies. We also excluded articles on
quality of life of combined pancreas-kidney transplant
recipients. Of articles with similar or overlapping
researchers or articles from the same center, we evalu-
ated their independence by determining when, where
and how many subjects were included. If more than
one published article reported data from the same
subjects, the most recent article was selected, unless its
sample was smaller or less information on covariates
was reported.
SF-36
The SF-36 consists of eight dimensions, generating
a proﬁle of health-related quality of life [13]. These
dimensions are: 1) Physical Functioning; 2) Role Limi-
tations due to Physical Functioning; 3) Bodily Pain; 4)
General Health Perceptions; 5) Vitality; 6) Social
Functioning; 7) Role Limitations due to Emotional
Functioning; and 8) Mental Health. Raw scores are
transformed into a score between zero and hundred for
each dimension. Higher scores indicate better health.
Data Extraction
A standardized data sheet was used to collect the data
from the studies. Data were extracted by one reader
(Y.S.L.) and independently veriﬁed by two others
(J.L.B., M.H.H.). Discrepancies were resolved by dis-
cussion. Readers were not blinded to information
about the authors, author afﬁliation, and journal
name, because this has been shown to be unnecessary
[14]. The extracted study characteristics included
publication year, country and center of authors and
patients, number of patients included, demographic
and clinical patient characteristics and the eight SF-36
dimension scores. If discrepancies in numbers existed
between text and tables, we extracted the number
reported in the table. If SF-36 scores had to be read
from a graph, we rounded off to the nearest 0.5 points.
If the study reported quality of life at multiple time-
points, we chose one time-point closest to the mean
time on therapy for the treatment group. For studies
evaluating interventions, such as immunosuppressive
regimens or exercise programs, we selected the base-
line time-point to minimize the effect of interventions
on the mean quality-of-life estimates, unless the inter-
vention started at the initiation of the RRT. If the time
of interview in relation to time on treatment was not
reported we chose the time-point for which sample size
and age were reported and if this information was
available for all time-points we chose the time-point
for which most demographic or clinical information
was available.
If treatment groups were split up according to cova-
riates, we preferred to use data of the total group, if
reported. If, however, more demographic or clinical
information was available for the split groups we
included these groups as separate entries into the
meta-analysis.
Data Synthesis and Analysis
We explored the data, testing for homogeneity of the
variables age, sex, diabetes, time on RRT, and SF-36
dimension scores within the three treatment groups
separately. After, we calculated pooled weighted means
and 95% conﬁdence intervals for these variables using
random-effects models, also for the three treatment
groups separately. Random-effects models weigh the
outcomes of the study according to the within-trial as
well as the between-trial variance [15]. We tested for
statistically signiﬁcant differences between the groups,
using Students’ t-tests and chi-square tests. In a
random-effects meta-regression analysis [16,17] we
corrected the differences in SF-36 scores between the
treatment groups for the covariates age and comorbid-
ity (diabetes mellitus), for the subgroup of studies for
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which this information was available. These covariates
have been reported to be independent predictors of
quality of life among RRT patients. We also performed
a subanalysis of all studies reporting time on RRT to
evaluate its effect on differences in SF-36 scores
between the treatment groups. To account for multiple
testing, we considered a P-value < 0.01 to reﬂect sta-
tistical signiﬁcance for all statistical tests and models.
For the analyses we used SAS 8.02 (SAS Institute Inc.,
Cary, NC, USA).
Results
Our literature search resulted in 192 articles. Of these
articles we excluded 35 on the basis of the abstract: 2
were excluded because they concerned a thesis or book,
5 because they were review articles, 11 because quality
of life of a different patient group was reported, 7
because quality of life of renal donors was reported, 2
because patients had predialysis renal insufﬁciency, 3
because quality of life of caregivers was reported, 2
because the sample included less than 10 patients, and 3
because no mean SF-36 scores were reported. Of the
remaining 157 articles, we excluded 105 on the basis of
the full text, for the following reasons: other quality-of-
life measurement techniques were used (N = 2), sample
size was not reported (N = 4) or less than 10 patients
were analyzed (N = 1), mean SF-36 scores were not
reported for all eight dimensions (N = 66), patients
with predialysis renal insufﬁciency were included
(N = 3), scores among combined groups were reported
(e.g., HD and PD patients, or HD, PD, and RTx
patients; N = 12), and plausible overlap with another
included article (N = 17). Exclusion of these studies
ensured included studies to be of good quality and all
included studies were of at least level 2b evidence
according to the Oxford Center for Evidence-Based
Medicine classiﬁcation [18]. One intervention study
was initiated directly after RTx [19] and did not report
absolute scores at a well-deﬁned follow-up point, there-
fore we used the baselinemeasurements from this study.
In our meta-analysis, we included 52 studies, that
reported on the quality of life of 92 groups of patients
on RRT measured with the SF-36 [1,8,12,19–67];
quality of life was reported for 44 HD groups (30,372
patients), 20 PD patient groups (3262 patients), and
28 RTx groups (2948 patients) (Tables of SF-36 scores
and selected study and patient characteristics for all
groups from the individual studies are available on-
line at http://www.ispor.org/valueinhealth_index.asp).
Tests for homogeneity were statistically signiﬁcant for
all variables, meaning that the null hypothesis of
homogeneity was rejected. Therefore, using random-
effects rather than ﬁxed-effects models appears to
be justiﬁed. Mean age, computed using random-
effects models, was not signiﬁcantly different for HD
(55.8 years) compared with PD (52.9 years) (P =
0.085) patients but RTx recipients (mean age =
43.7 years) were signiﬁcantly younger than dialysis
patients (P < 0.001) (Table 1). The majority of patients
were male and there were no statistically signiﬁcant
differences in sex distribution among the three treat-
ment groups (P > 0.039). Prevalence of diabetes was
24% among HD, 17% among PD, and 7% among
RTx patients, with a signiﬁcant difference for the HD
to RTx patient comparison (P < 0.001). This preva-
lence might be lower than that reported by the United
States Renal Data System, because most studies are
from other countries than the United States and in
general, prevalence of diabetes is known to be lower in
Europe and Asia. The mean treatment time was
44.1 months for HD patients, 24.3 months for PD,
and 63.8 months for RTx recipients. Comparing all
treatment groups, PD and RTx patients had a signiﬁ-
cantly different mean time on treatment (P = 0.001).
In general, SF-36-dimension scores were signiﬁ-
cantly lower for HD and PD compared with RTx
patients (Fig. 1) (P < 0.01), except for the Mental
Health dimension for which PD scores were not sig-
niﬁcantly different from scores of RTx recipients (P =
0.019). Scores of HD compared with PD patients were
not statistically signiﬁcantly different (P > 0.055).
We found 23 studies that reported the percentage
of patients with diabetes mellitus in 47 patient groups
[8,21,22,24–26,30–33,37,40,44,46,47,51,53,56,58,
61–63,66]. The random-effects means of the SF-36
scores computed from these studies (Table 2) were very
similar to those computed from all studies (Fig. 1).
Signiﬁcance of the differences between treatment
groups was also similar, except for the Bodily Pain
Table 1 Demographic and clinical characteristics of renal replacement therapy patients
Hemodialysis Peritoneal dialysis Renal transplantation
N Mean* 95% CI N Mean* 95% CI N Mean* 95% CI
Mean age (years) 43 55.8 (53.9–57.7) 20 52.9 (50.1–55.7) 27 43.7 (41.3–46.0)
Proportion male 37 0.55 (0.52–0.58) 18 0.55 (0.50–0.59) 17 0.61 (0.57–0.65)
Proportion with diabetes 24 0.24 (0.18–0.30) 14 0.17 (0.11–0.26) 9 0.07 (0.04–0.12)
Mean time on treatment
(months)
32 44.1 (32.9–55.3) 12 24.3 (6.1–42.5) 21 63.8 (50.1–77.6)
*Mean based on random-effects model.
CI, conﬁdence interval; N, number of groups.
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dimension (no signiﬁcant difference in score between
PD and RTx patients) and the Mental Health dimen-
sion (no signiﬁcant difference between HD and RTx
patients). The point differences of the scores of the
dialysis groups compared with the RTx group varied
from 2 to 32.
In random-effects meta-regression analyses, we cor-
rected for age and diabetes. The covariates did not
attain statistical signiﬁcance in many of the regression
models. Only in the regression models estimating the
Role Physical score and the Vitality score, the age
covariate was associated with a P-value lower than
0.01. From the regression analyses and the mean age
(52.9 years) and proportion with diabetes (0.16) in the
total population we computed adjusted scores (see
Table 3). Compared with the unadjusted scores, the
adjusted scores were higher for HD patients and lower
for RTx recipients. The adjusted scores of PD patients
were similar to the unadjusted scores. Thus, in general,
the differences between the groups became smaller.
This is also reﬂected in the point differences of the
adjusted scores of the dialysis groups compared with
the RTx group, which varied from 2 to 22 (unadjusted:
2–32). After adjustment, the signiﬁcance of the differ-
ences of both dialysis groups compared with RTx
recipients disappeared for the Vitality dimension and
the Social Functioning dimension. In addition, the sig-
niﬁcance of the differences between HD and RTx
patients disappeared on the Physical Functioning, the
Role Physical, and the Bodily Pain dimensions. The
nonsigniﬁcantly lower score of PD as compared with
HD patients on the Role Physical dimension became
statistically signiﬁcant. In random-effects meta-
regression analyses including time on replacement
therapy, this variable did not show any effect on exist-
ing differences in SF-36 scores between the three treat-
ment groups. In the subgroup of studies that reported
age and diabetes as well as time on therapy, it did have
an independent effect on the signiﬁcance of three PD
versus RTx comparisons. But in a meta-regression
model adjusted for age and diabetes as well as time on
RRT, the additional effect of time on therapy only
persisted for one PD versus RTx comparison. Because
we did not want to include too many covariates
and because the additional effect of time on RRT was
negligible, it was not included as a covariate in the full
meta-regression model.
Discussion
The present meta-analysis corroborates the consensus
that health-related quality of life differs across the
different forms of RRT. Except for the Mental Health
dimension, health-related quality of life as mea-
sured by the SF-36 was higher among RTx patients
than among dialysis patients. SF-36 scores among
HD patients compared with PD patients were not
statistically signiﬁcantly different. Nevertheless, meta-
regression analyses revealed that some of the differences
in scores between dialysis patients and RTx recipients
Figure 1 SF-36 scores from all articles: random-effects-model means. BP,
Bodily Pain; GH, General Health Perceptions; MH, Mental Health; PF,
Physical Functioning; RE, Role Limitations due to Emotional Functioning;
RP, Role Limitations due to Physical Functioning; SF, Social Functioning;VT,
Vitality.
Table 2 SF-36 scores from articles that reported the percentage of patients with diabetes (N = 23 studies)
HD PD RTx P-value*
Mean† 95% CI Mean† 95% CI Mean† 95% CI HD vs. PD HD vs. RTx PD vs. RTx
PF 51.5 (46.7–56.2) 53.6 (47.2–60.0) 74.8 (67.1–82.5) 0.594 <0.001 <0.001
RP 45.1 (39.8–50.4) 34.1 (26.9–41.4) 66.3 (57.5–75.0) 0.017 0.001 <0.001
BP 60.2 (57.2–63.2) 66.1 (62.0–70.2) 74.0 (69.1–78.9) 0.025 <0.001 0.016
GH 42.4 (40.2–44.5) 45.5 (42.6–48.5) 57.9 (54.5–61.4) 0.087 <0.001 <0.001
VT 47.8 (44.8–50.8) 46.1 (42.0–50.2) 58.6 (53.7–63.4) 0.504 <0.001 <0.001
SF 61.7 (57.4–66.1) 65.5 (59.7–71.3) 79.1 (72.1–86.2) 0.304 <0.001 0.005
RE 51.5 (47.0–56.0) 55.3 (49.0–61.7) 73.9 (66.4–81.4) 0.325 <0.001 <0.001
MH 63.7 (60.9–66.5) 67.2 (63.4–71.0) 69.5 (64.9–74.1) 0.147 0.034 0.435
*Conclusions as to signiﬁcance of difference from the conﬁdence intervals is slightly different than from the P-value because of the fact that the distributions of the scores are
ﬂat and not entirely normal.
†Mean based on random-effects model.
BP, Bodily Pain; CI, conﬁdence interval; GH, General Health Perceptions; HD, hemodialysis; MH,Mental Health; PD, peritoneal dialysis; PF, Physical Functioning; RE, Role Limitations
due to Emotional Functioning; RP, Role Limitations due to Physical Functioning; RTx, renal transplantation;VT,Vitality; SF, Social Functioning.
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could be partly explained by differences in age and
presence of diabetes between these treatment groups.
Changes in SF-36 scores after adjustment were
more pronounced for HD and RTx patients as com-
pared with PD patients, since the average mean age
and prevalence of diabetes in PD patients was closer to
the average mean age and prevalence of diabetes across
all treatment groups. This may explain why the differ-
ences between scores of PD patients and RTx patients
disappeared with adjustment for only two dimensions,
whereas with adjustment, the differences in scores dis-
appeared in ﬁve dimensions for HD compared with
RTx patients.
Wu and colleagues [67] report both unadjusted
SF-36 scores and scores adjusted for age, sex, race,
education, albumin, creatinine, hematocrit, and
comorbidity score for HD and PD patients after 1 year
of dialysis treatment. Unadjusted scores of PD patients
were signiﬁcantly higher for the Bodily Pain dimension
and lower for the Vitality dimension. After adjustment,
the difference in Vitality disappeared, but the differ-
ence in Bodily Pain remained. Nevertheless, all differ-
ences were borderline signiﬁcant (P-value between
0.03 and 0.05). Merkus and colleagues showed that a
signiﬁcantly higher unadjusted quality of life of PD
patients as measured on four dimensions of the SF-36
only persisted for the Mental Health dimension after
adjustment [44].
From their study among HD, PD, and RTx patients
and patients receiving conservative therapy, Baiardi
and colleagues [21] conclude that treatment method
and age independently inﬂuenced quality of life.
Dimensions most affected were Physical Functioning,
Bodily Pain, General Health, and Vitality. Scores for
the four dimensions corrected for mean age and hemo-
globin level showed that for the Physical Functioning
and Bodily Pain dimensions, patients receiving conser-
vative treatment and RTx patients had better results
than those on dialysis. Similar to our results, compared
with their unadjusted scores the adjusted scores of HD
patients were in general higher and the adjusted scores
of RTx patients were lower. Adjusted scores of PD
patients were only slightly higher than unadjusted
scores. In general, differences across the treatment
groups became smaller. Adjusted differences in quality
of life between dialysis and RTx patients might be
smaller than generally thought because RTx patients
commonly have a long history including dialysis,
which affects their quality of life.
In a meta-analysis of emotional distress and psycho-
logical well-being of HD, PD, and RTx patients,
Cameron and colleagues reported comparable differ-
ences in quality of life [6]. The authors did not
formally adjust for covariates inﬂuencing these differ-
ences, but did report differences in covariates among
the treatment modalities. They concluded that because
RTx patients are generally younger, healthier, more
highly educated, and more likely to be employed, it
cannot be ruled out that differences in emotional dis-
tress and psychological well-being are partly a result of
differences in case mix.
To be able to assess real differences in quality of life
among RRT patients, Cameron and colleagues sug-
gested a prospective repeated-measures experimental
design in which the same cohort of patients can be
assessed repeatedly and at clinically signiﬁcant mile-
stones, such as when a patient switches to a different
treatment modality [6]. Nevertheless, such switches
are usually induced by changes in demographic or
clinical variables, so analysis of data from such a study
should still be adjusted for case-mix variables. Another
solution the authors suggested was to limit research
participants to those patients for whom any form of
RRT would be equally suitable. Results, however,
would not be generalizable to the entire patient popu-
lation. This problem is also relevant to our meta-
regression analyses, because we used the average mean
age and proportion with diabetes across all treatment
groups to calculate adjusted scores. Adjusted scores
should therefore not be interpreted as actual scores.
More interesting is the direction of the change of
the scores after adjustment and the signiﬁcance of the
Table 3 SF-36 scores from articles that reported the percentage of patients with diabetes adjusted for age and diabetes
HD PD RTx P-value*
Mean† 95% CI Mean† 95% CI Mean† 95% CI HD vs. PD HD vs. RTx PD vs. RTx
PF 55.4 (50.1–60.7) 54.4 (48.3–60.5) 69.4 (60.6–78.2) 0.801 0.017 0.007
RP 49.9 (44.2–55.5) 34.2 (27.7–40.6) 56.4 (47.1–65.8) <0.001 0.283 <0.001
BP 63.3 (59.9–66.7) 66.7 (62.9–70.6) 69.5 (64.1–75.0) 0.163 0.087 0.404
GH 43.5 (40.8–46.1) 45.8 (42.8–48.7) 56.4 (52.1–60.6) 0.230 <0.001 <0.001
VT 50.1 (47.2–53.1) 45.7 (42.3–49.0) 51.7 (46.9–56.5) 0.042 0.630 0.047
SF 64.2 (59.0–69.4) 66.1 (60.4–71.9) 76.3 (67.9–84.8) 0.610 0.032 0.051
RE 51.8 (46.4–57.3) 55.0 (48.6–61.4) 71.9 (62.8–81.0) 0.432 0.001 0.004
MH 64.0 (60.5–67.5) 67.2 (63.3–71.1) 69.0 (63.3–74.7) 0.203 0.186 0.616
*Conclusions as to signiﬁcance of difference from the conﬁdence intervals is slightly different than from the P-value because of the fact that the distributions of the scores are
ﬂat and not entirely normal.
†Mean based on random-effects model.
BP, Bodily Pain; CI, conﬁdence interval; GH, General Health Perceptions; HD, hemodialysis; MH,Mental Health; PD, peritoneal dialysis; PF, Physical Functioning; RE, Role Limitations
due to Emotional Functioning; RP, Role Limitations due to Physical Functioning; RTx, renal transplantation;VT,Vitality; SF, Social Functioning.
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differences of adjusted scores among the treatment
groups.
There are several limitations to our study that should
be mentioned. First, the results of meta-analyses always
rely on completeness of available published literature.
Thus, they are known to be inﬂuenced by publication
bias. Nevertheless, ours is a study of mostly noncom-
parative studies and from the comparative studies that
we included only absolute measures were extracted. So
if publication bias should have affected our study, its
effect can be assumed to be very small.
Second, we would have wanted to adjust for all
possible case-mix differences that might inﬂuence
reported health-related quality of life. Age, sex, ethnic-
ity, socioeconomic status, education, employment, and
income are considered to be independent demographic
predictors of quality of life [68]. Additionally, several
disease-associated factors such as primary renal
disease, treatment history, anemia and comorbid
disease are also known to be associated with quality of
life [68]. Unfortunately, not all these covariates were
consistently published in the studies and the number of
studies was too small to be able to correct for many
case-mix differences. Therefore, we decided to only
adjust for case mix in a subset of studies and for a
limited number of covariates. But even if more studies
reporting all these covariates would have been avail-
able, caution is required in selecting covariates for the
regression analysis. Covariates need to be prespeciﬁed
to avoid data dredging [17]. Furthermore, results are
easier to interpret when the covariate has a high vari-
ability across studies compared with within studies.
But still, interpretation of meta-regression analyses
using patient covariates is not always straightforward
because of the fact that the relationship of the outcome
with patient averages across trials may not be the same
as the relationship of the outcome across patients
within trials. This phenomenon is also referred to as
aggregation bias or the ecologic fallacy [17].
Lambert and colleagues compared a meta-
regression analysis using mean patient covariates to an
analysis with individual patient-level data [69]. They
found that although the estimates from the meta-
regression analysis were not biased, there was a greater
variation for the meta-regression estimates than for the
estimates from the analysis on the individual patient-
level data. They concluded that to investigate whether
patient characteristics are related to treatment, a meta-
analysis of summary data might not be apt and that an
individual-patient-level data analysis will generally be
necessary to uncover such relationships. We did,
however, ﬁnd signiﬁcant changes with adjustment.
From this meta-analysis we conclude that HD and
PD patients tend to have a lower quality of life than
RTx recipients. Quality of life seems comparable for
HD and PD patients. Adjusting the SF-36 scores for
mean age and prevalence of diabetes in a meta-
regression analysis showed that some differences in
scores between dialysis and RTx patients can be partly
explained by unequal patient selection for the different
RRT modalities. This implies that although quality of
life of dialysis patients is worse than that of RTx
recipients, the difference between these groups might
not be as big as generally thought. This is important in
choosing an appropriate therapy for an individual
patient. In targeting interventions aimed at improving
quality of life, factors independently associated with
quality of life, such as comorbidity, should also be
taken into account.
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